Crescita Therapeutics Inc. Announces Closing of Arrangement
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of the Company (the “Shares”) in exchange for cash consideration of $0.80 per Share (the “Consideration”).
The Company’s Shares will be delisted from the Toronto Stock Exchange (“TSX”) and the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.
To receive the Consideration under the Arrangement, each registered holder of Shares (each a “Shareholder”) must complete, sign and deliver to TSX Trust Company, as depositary under the Arrangement, the letter of transmittal that accompanied the Company’s management information circular dated April 10, 2026 together with any other documents required thereby. Non-registered shareholders of the Company must contact the intermediary in whose name their Shares are registered for instructions and assistance in receiving the Consideration in respect of their Shares.
